SCHEMBL13610476

SCHEMBL13610476

c1ccc(CSSSCc2csc3ccccc23)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.45
SMN1; SMN2 Q16637 6/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
CHRNA7 P36544 1/20 0.38
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
LMNA P02545 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.36
IDO1 P14902 1/20 0.36
ALDH1A1 P00352 4/20 0.35
CYP1A2 P05177 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.34
CASP3 P42574 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13610504 0.85 CYP2A6 (0.42) CYP2A6SMN1; SMN2RAB9ACHRNA7CRHBP
SCHEMBL4267991 0.85 CYP2A6 (0.60) CYP2A6SMN1; SMN2CHRNA7CRHBPCRHR2
SCHEMBL13610526 0.73 SMN1; SMN2 (0.45) CYP2A6SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL13610434 0.72 FFAR2 (0.42) CYP2A6SMN1; SMN2CHRNA7CRHBPCRHR2
SCHEMBL13780226 0.72 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9ALMNAKDM4E
SCHEMBL11445226 0.71 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9ALMNAKDM4E
SCHEMBL13610468 0.71 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9ALMNAKDM4E
SCHEMBL13610304 0.70 CYP2A6 (0.43) CYP2A6SMN1; SMN2MAPTIDO1CASP3
SCHEMBL13610474 0.69 RAB9A (0.60) SMN1; SMN2NPC1RAB9AKDM4EMAPT
SCHEMBL13610457 0.69 CYP2A6 (0.39) CYP2A6SMN1; SMN2CHRNA7CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742635-B1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES INC (US) 2018-03-07 EP disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF TST, CTH, CBS CYP2A6 2406/4885SMN1; SMN2 1171/4885NPC1 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.